Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 100.02

-0.3%

10:44 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William L. Oppenheim who wrote (347)	10/20/1998 1:42:00 AM
From: Mike	Read Replies (1) of 687

Medtronic has a pe that should be of concern. Remember that the company had a writeoff of the vascular division last year that brought earnings down approx 0.30/share. When you add this nonrecurring charge back in it drops the pe slightly. I know this is minor but something to consider when looking at valuations. In addition, most of the growth for MDT will be in the back half of this fiscal year. The current second qtr for MDT is about to end on Oct 31. Look for big growth from the new Gem DR defib which was just FDA approved. This is a major shot in the arm for the CRM unit of MDT. This will have a major impact on the numbers next qtr. Let us know your further thoughts on the valuation. Best of luck, Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next